Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone626-350-0537
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.36 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/6/2019 (Estimated)
OptionableNot Optionable
Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions
What is Fulgent Genetics' stock symbol?
Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."
How were Fulgent Genetics' earnings last quarter?
Fulgent Genetics Inc (NASDAQ:FLGT) issued its quarterly earnings data on Thursday, February, 28th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.02. The company had revenue of $5.68 million for the quarter, compared to the consensus estimate of $5.90 million. Fulgent Genetics had a negative return on equity of 6.90% and a negative net margin of 21.02%. View Fulgent Genetics' Earnings History.
When is Fulgent Genetics' next earnings date?
What price target have analysts set for FLGT?
2 brokers have issued 1 year price objectives for Fulgent Genetics' shares. Their predictions range from $5.00 to $5.10. On average, they anticipate Fulgent Genetics' stock price to reach $5.05 in the next twelve months. This suggests that the stock has a possible downside of 8.2%. View Analyst Price Targets for Fulgent Genetics.
What is the consensus analysts' recommendation for Fulgent Genetics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fulgent Genetics.
Has Fulgent Genetics been receiving favorable news coverage?
Media stories about FLGT stock have trended positive on Sunday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fulgent Genetics earned a news sentiment score of 2.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of Fulgent Genetics' key competitors?
Some companies that are related to Fulgent Genetics include Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), First Choice Healthcare Solutions (FCHS), CBA Florida (CBAI), OpGen (OPGN), Cancer Genetics (CGIX), Aeon Global Health (AGHC), Biocept (BIOC), Avant Diagnostics (AVDX) and Foundation Medicine (FMI).
What other stocks do shareholders of Fulgent Genetics own?
Who are Fulgent Genetics' key executives?
Fulgent Genetics' management team includes the folowing people:
- Mr. Ming Hsieh, Chairman, CEO & Pres (Age 63)
- Mr. Paul Kim, Chief Financial Officer (Age 52)
- Dr. Han Lin Gao, Chief Scientific Officer & Lab Director (Age 52)
When did Fulgent Genetics IPO?
(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.
Who are Fulgent Genetics' major shareholders?
Fulgent Genetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Old West Investment Management LLC (2.40%), Mutual Advisors LLC (1.08%), Essex Investment Management Co. LLC (0.46%), Essex Investment Management Co. LLC (0.46%), Royce & Associates LP (0.21%) and Brown Advisory Inc. (0.08%). Company insiders that own Fulgent Genetics stock include Ming Hsieh and Paul Kim. View Institutional Ownership Trends for Fulgent Genetics.
Which institutional investors are selling Fulgent Genetics stock?
Which institutional investors are buying Fulgent Genetics stock?
FLGT stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Essex Investment Management Co. LLC, Old West Investment Management LLC, Brown Advisory Inc. and Financial Advisors LLC. View Insider Buying and Selling for Fulgent Genetics.
How do I buy shares of Fulgent Genetics?
Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fulgent Genetics' stock price today?
One share of FLGT stock can currently be purchased for approximately $5.50.
How big of a company is Fulgent Genetics?
Fulgent Genetics has a market capitalization of $99.39 million and generates $21.36 million in revenue each year. The company earns $-4,490,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis.
What is Fulgent Genetics' official website?
How can I contact Fulgent Genetics?
Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]
MarketBeat Community Rating for Fulgent Genetics (NASDAQ FLGT)
MarketBeat's community ratings are surveys of what our community members think about Fulgent Genetics and other stocks. Vote "Outperform" if you believe FLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
